Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency

AIDS

Volumn 22, Issue 18, 2008, Pages 2501-2508

  Harrigan, P Richard ^a   Sheen, Chih Wei ^b   Gill, Vikram S ^a   Wynhoven, Brian ^a   Hudson, Erin ^a   Lima, Viviane D ^a   Lecocq, Pierre ^c   Aguirre, Rosalia ^d   Poon, Art F Y ^e   Sluis Cremer, Nicolas ^b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Virco BVBA   (Belgium)

^d The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Evolution; Highly active antiretroviral therapy; HIV 1; Reverse transcriptase; Synonymous mutation

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; PRIMER DNA; PRIMER RNA; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BIOASSAY; CODON; CONTROLLED STUDY; DISSOCIATION; DNA TEMPLATE; ENZYME ACTIVITY; ENZYME PURIFICATION; ENZYME SUBSTRATE; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION; STEADY STATE;

DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 57349200456     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328318f16c     Document Type: Article

References (21)

1. Warnke D, Barreto J, Temesgen Z. Antiretroviral drugs. J Clin Pharmacol 2007;47:1570-1579.
2. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417-2426.
3. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007;15:119-125.
4. Menendez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 RT. Virus Res 2008;134:124-146.
5. Brookes AJ. The essence of SNPs. Gene 1999;234:177- 186.
6. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-528.
7. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568- 2577.
8. Brumme ZL, Brumme CJ, Heckerman D, Korber BT, Daniels M, Carlson J, et al. Evidence of differential HLA class l-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007;3:e94.
9. Sluis-Cremer N, Arion D, Parikh U, Koontz D, Schinazi RF, Mellors JW, et al. The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem 2005;280:29047-29052.
10. Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 RT. AIDS 2007;21:1405-1414.
11. Le Grice SF, Gruninger-Leitch F. Rapid purification of homodimer and heterodimer HIV-1 RT by metal chelate affinity chromatography. Eur J Biochem 1990;187:307-314.
12. Le Grice SF, Cameron CE, Benkovic SJ. Purification and characterization of human immunodeficiency virus type 1 RT. Methods Enzymol 1995;262:130-144.
13. Kati WM, Johnson KA, Jerva LF, Anderson KS. Mechanism and fidelity of HIV RT. J Biol Chem 1992;267:25988-25997.
14. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 RT exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006;80:4971-4977.
15. Parikh UM, Barnas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 2006;194:651-660.
16. Svicher V, Alteri C, Lagana A, Pigola G, Dimonte S, Mussini C, et al. Synonymous mutations in the highly ordered regulation of nucleoside RT inhibitor resistance [abstract]. Antivir Ther 2008;13 (Suppl 3):A62.
17. Gonzalez LMF, Pinto AFN, Martins AN, Ahuiar RS, Afonso AO, Brindeiro RM, et al. Silent mutations at RT codons 65 and 66 in B and C strains found in Brazil are very strongly associated with treatment and these signatures can impact on zidovudine mutation acquisition in vitro [abstract]. Antivir Ther 2008;13 (Suppl 3):A63.
18. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C RT (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002;46:2087- 2094.
19. Turner D, Brenner B, Moisi D, Detorio M, Cesaire R, Kurimura T, et al. Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:2993-2998.
20. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006;20:F9-F13.
21. Invernizzi CF, Coustinos D, Moisis D, Oliveira M, Spira B, Brenner B, Wainberg M. Introduction of the 64/65 nucleotide polymorhpisms of subtype C into subtype B HIV-1 selects for the K65R mutational pathway in cell culture [abstract]. 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston.